Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
5,625,789
-
Share change
-
-3,852,805
-
Total reported value
-
$6,582,396
-
Put/Call ratio
-
4.5%
-
Price per share
-
$1.17
-
Number of holders
-
64
-
Value change
-
-$4,774,740
-
Number of buys
-
38
-
Number of sells
-
39
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q2 2024
As of 30 Jun 2024,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
64 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,625,789 shares.
The largest 10 holders included
MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, GOLDMAN SACHS GROUP INC, NORTHERN TRUST CORP, GSA CAPITAL PARTNERS LLP, BlackRock Inc., JANE STREET GROUP, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Y-Intercept (Hong Kong) Ltd, and SUSQUEHANNA INTERNATIONAL GROUP, LLP.
This page lists
65
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.